What do you call the PSA phase 2 trial that`s wrapping up with end data? Phase 3 is probably right around the corner,and on Merck`s dime not Adxs`s this go around,so how does`nt that put us ahead of where we are with Cervix,even if they do wind it down? PSA`s worth more in market cap,and with Merck paying for a phase 3,it`s likely they`ll partner for it in the end, just saying it`s a likely outcome if Ken can`t get them to make a big partnership deal on PSA/Axal n HOT for it,because they`re not convinced enough to shell out the huge cash yet,but they`d pay for a phase 3 to see if it`s worth it,don`t you think? Thereby making us a late stage bio in a phase 3 trial.Plus if they did it next year and it finished in early 2020 it would still be ahead of the Cervix AIM2CERV. Could be the plan